Call for Comment: SITC invites public review of the new draft clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma v3.0. Deadline for feedback is May 8. More at: ow.ly/FBAq50VFKQj

#SITCGuidelines #RCC #KidneyCancer #RenalCancer #Cancer 🧪

Last chance! Call for Comment: SITC invites public review of the new draft clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma v3.0. Submit your comments by May 8: sitcancer.org/research/can...

#SITCGuidelines #RCC #KidneyCancer 🧪

SITC’s Lymphoma CPG update includes the latest guidance in the rapidly changing treatment landscape, addressing several new IO approvals for ICIs, ADCs, CAR T cell therapies, and bispecific antibodies.
Learn more: ow.ly/4Zft50VpHwk

#SITCGuidelines #Lymphoma #Immunotherapy #OncSky #MedSky #cancer

SITC’s new Melanoma CPG Addendum addresses the changing treatment landscape driven by the first approved solid tumor cell therapy, lifileucel, and practice-changing guidance from the NADINA trial. Learn more here: ow.ly/5G0w50VlqHK
#SITCGuidelines #Melanoma #Immunotherapy
@jasonlukemd.bsky.social

Want to play a key role in shaping policies and strategies for guideline development and dissemination? SITC is seeking volunteers to serve on the Cancer Immunotherapy Guidelines Oversight Committee. Learn More: ow.ly/ou4t50V9C0q
#volunteer #SITCGuidelines #OncSky

SITC’s new Lung Cancer CPG Addendum provides up-to-date guidance in rapidly evolving treatment landscapes driven by several new cancer immunotherapy approvals in #NSCLC and #SCLC. Learn more here: jitc.bmj.com/content/10/5... #SITCGuidelines #LungCancer #Immunotherapy